Case Report

Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis

Shelley J. E. Hwang,1,2 Benjamin Y. Kong,3 Shaun Chou,4 Deepal Wakade,1,2 Matteo S. Carlino,2,3,5 and Pablo Fernandez-Penas1,2

1Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia
2Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
3Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia
4Department of Tissue Pathology, Westmead Hospital, Westmead, NSW, Australia
5Melanoma Institute Australia, Sydney, NSW, Australia

Correspondence should be addressed to Shelley J. E. Hwang; shelley.hwang@hotmail.com

Received 19 August 2016; Revised 2 December 2016; Accepted 20 December 2016; Published 15 January 2017

Academic Editor: Giuseppe Micali

Copyright © 2017 Shelley J. E. Hwang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There are reported cases of diphencyprone used in treating cutaneous metastases of melanoma. Here, we report a patient with previous primary melanoma on his left back treated with surgical excision and lymphadenectomy, followed by radiotherapy for the recurrent tumor on the primary site. Despite radiotherapy and treatment with dabrafenib and trametinib, in-transit metastases have developed and topical diphencyprone was applied to these metastases. Six weeks later, the patient developed fever and a spreading erythematous tender indurated plaque covering the left side of the body including axillae, back, and flank, clinically suggestive of cellulitis. Systemic antibiotic therapy did not improve the condition and a biopsy showed sparse lymphocytic infiltrate. With the diagnosis of possible acute lymphedema, a CT scan was requested that showed significant axillary lymph node metastasis. The fever was considered secondary to dabrafenib and trametinib therapy. This case highlights that, in patients with lymphadenectomy, atypical forms of lymphedema on the body may appear. Truncal lymphedema is an infrequent event.

1. Manuscript

Upper limb lymphedema commonly complicates the detection and management of axillary nodal metastasis from melanoma, and its prevalence after radical axillary dissection for melanoma is reported to vary from 1 to 12% [1]. However, lymphedema affecting the trunk is rarely described; hence considering this as a differential diagnosis would be unusual.

A 68-year-old Caucasian male presented with rapidly progressing local recurrence and in-transit deposits of cutaneous melanoma on his left upper back. A primary BRAFV600E positive 0.9 mm Breslow thickness superficial spreading malignant melanoma was treated with wide local excision the previous year, which recurred within five months and he was found to have in-transit metastasis with left axillary palpable lymphadenopathy. He subsequently received a level I–III axillary dissection (10 of 34 lymph nodes were positive for melanoma) together with an adjuvant high dose radiotherapy (55 Gy in 20 fractions). Despite locoregional radiotherapy, cutaneous recurrences appeared within the irradiated field of his primary site. Subsequently, the patient was commenced on the combination of dabrafenib and trametinib. Four months later, topical immunotherapy with diphencyprone (DPCP) was commenced as an adjunct therapy [2–5] to the locoregional metastasis. Concurrently, the patient was initiated on low dose oral prednisone (20 mg daily) to control fever from dabrafenib and trametinib.

After four applications of DPCP, the patient developed mild erythema around the cutaneous metastasis but not on the melanoma deposits. Betamethasone valerate cream was applied to the surrounding skin, and as there were no signs of adequate reaction achieved on the lesions, the frequency of
DPCP application was increased. Dabrafenib and trametinib were ceased due to worsening systemic adverse events (fever, nausea, and vomiting).

Twelve days later, the patient presented with extensively spread erythematous reaction on his left upper and lower back (Figure 1(a)), axilla, flank, and abdomen (Figure 1(b)). The reaction was limited to midline of his back. He had fever and elevated white cell count. The differential diagnosis of allergic contact dermatitis and cellulitis was considered. A skin biopsy was taken and empirical oral flucloxacillin was commenced whilst DPCP was ceased.

Two days later, due to worsening cutaneous reaction and persistent fever, he was hospitalized to receive intravenous flucloxacillin. Repeated blood cultures were negative. A skin biopsy showed only mild psoriasiform hyperplasia, occasional dermal eosinophils, and no neutrophils. The patient was commenced on a weaning dose of oral prednisone to reduce inflammation.

Two weeks later, the skin became sclerodermatoid and an incisional skin biopsy showed focal parakeratosis, mild superficial perivascular chronic inflammation, patchy papillary dermal edema, and vascular ectasia. There was no spongiosis or significant acute inflammation. A consensus of acute lymphedema secondary to potentially failed lymphatic drainage from underlying recurrence of the disease was made. Computed tomography (CT) scans of the chest, abdomen, and pelvis confirmed recurrence of tumor at left axillae. Subsequently, the patient was commenced on pembrolizumab. Unfortunately, the patient deteriorated and passed away in four weeks.

Limb lymphedema is a common complication related to radical lymph nodes clearance [1]. However, lymphedema affecting the trunk is substantially less common [6]. It has been reported that truncal lymphedema involving chest, axilla, shoulder, breast, and back regions can appear in some breast cancer survivors [7, 8]. As high as 48% patients with breast cancer who had undergone axillary dissection with positive nodes are reported to develop breast edema a year after the surgery [9]. However, there is a lack of literature describing truncal lymphedema appearing in patients with advanced melanoma.

Our case illustrates a cellulitis-like clinical presentation on the trunk that masked acute lymphedema from secondary axillary metastasis. This is more relevant in patients with advanced melanoma who have progressed whilst on targeted therapy [10]. In our case, the differential diagnoses were difficult to ascertain as treatment with DPCP could trigger acute contact eczema with a similar clinical presentation. Although the activity of DPCP could have been a factor in the development of this atypical form of lymphedema, the absence of inflammation in the biopsies does not support it.

Our case highlights that, in patients with lymphadenectomy for melanoma, atypical forms of lymphedema on the body may appear. Truncal swelling mimicking cellulitis may be an early clinical sign of underlying tumor progression. However, being an infrequent event, it may be challenging for clinicians to reach this diagnosis early.

**Abbreviations**

DPCP: Diphencyprone
CT: Computed tomography.

**Disclosure**

The information was presented (poster) on 14th to 17th of May 2016 at the Australasian College of Dermatologists 49th Annual Scientific Meeting held in Perth, Australia.

**Competing Interests**

Matteo S. Carlino is on advisory boards for Novartis, Merck, Sharpe and Dohme, Bristol-Myers Squibb, and Amgen. All other authors have no competing interests to declare.
Acknowledgments

The authors acknowledge Allan Fong (Outpatients Pharmacy, Westmead Hospital, Westmead, NSW, Australia) for compounding DPCP, Dr. Marina Ali (Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia and Sydney Medical School, The University of Sydney, Sydney, NSW, Australia), and Rupalben Patel (Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia) for administration assistance.

References

[1] E. C. Starritt, D. Joseph, J. G. McKinnon, S. K. Lo, J. H. W. de Wilt, and J. F. Thompson, "Lymphedema after complete axillary node dissection for melanoma: assessment using a new, objective definition," *Annals of Surgery*, vol. 240, no. 5, pp. 866–874, 2004.

[2] D. L. Damian, R. P. M. Saw, and J. F. Thompson, "Topical immunotherapy with diphenycyprone for in transit and cutaneously metastatic melanoma," *Journal of Surgical Oncology*, vol. 109, no. 4, pp. 308–313, 2014.

[3] T. Fujimura, S. Furudate, A. Kakizaki et al., "Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: two cases reports," *Journal of Dermatology*, vol. 43, no. 6, pp. 686–689, 2016.

[4] D. L. Damian, K. F. Shannon, R. P. Saw, and J. F. Thompson, "Topical diphenycyprone immunotherapy for cutaneous metastatic melanoma," *Australasian Journal of Dermatology*, vol. 50, no. 4, pp. 266–271, 2009.

[5] D. L. Damian and J. F. Thompson, "Treatment of extensive cutaneous metastatic melanoma with topical diphenycyprone," *Journal of the American Academy of Dermatology*, vol. 56, no. 5, pp. 869–871, 2007.

[6] C. C. Roberts, J. R. Levick, A. W. B. Stanton, and P. S. Mortimer, "Assessment of truncal edema following breast cancer treatment using modified Harpenden skinfold calipers," *Lymphology*, vol. 28, no. 2, pp. 78–88, 1995.

[7] R. Hansdorfer-Korzon, J. Teodorczyk, A. Gruszecka, J. Wydra, and P. Lass, "Relevance of low-pressure compression corsets in physiotherapeutic treatment of patients after mastectomy and lymphadenectomy," *Patient Preference and Adherence*, vol. 10, pp. 1177–1187, 2016.

[8] S. H. Ridner, B. Murphy, J. Deng et al., "A randomized clinical trial comparing advanced pneumatic truncal, chest, and arm treatment to arm treatment only in self-care of arm lymphedema," *Breast Cancer Research and Treatment*, vol. 131, no. 1, pp. 147–158, 2012.

[9] S. H. Ridner, B. Murphy, J. Deng, N. Kidd, E. Galford, and M. S. Dietrich, "Advanced pneumatic therapy in self-care of chronic lymphedema of the trunk," *Lymphatic Research and Biology*, vol. 8, no. 4, pp. 209–215, 2010.

[10] M. S. Carlino, K. Gowrishankar, C. A. B. Saunders et al., "Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma," *Molecular Cancer Therapeutics*, vol. 12, no. 7, pp. 1332–1342, 2013.